Bupa Finance PLC (02779134): Financial & Intelligence Profile
Executive Summary
Bupa Finance PLC (Company Number 02779134) functions as the primary intermediate holding and treasury management vehicle for the global healthcare group headed by The British United Provident Association Limited. The company issues debt securities listed on regulated markets and manages group liquidity across three main operating divisions: Health Insurance, Health Provision, and Aged Care. For the financial year ended 31 December 2025, the group reported turnover of £18.154 billion and a statutory profit before tax of £1.147 billion, supported by an operating cash flow of £1.426 billion and a Solvency II capital coverage ratio of 187%.
+--------------------------------------------------------------------------------+
| BUPA FINANCE PLC (02779134) |
| Corporate Structure & Role |
+--------------------------------------------------------------------------------+
|
+--------------------+--------------------+
| Ultimate Parent: Bupa Group |
| (Company Limited by Guarantee) |
+--------------------+--------------------+
|
v
+--------------------+--------------------+
| Issuer & Treasury: Bupa Finance PLC |
| (Company Number: 02779134) |
+--------------------+--------------------+
|
+------------------------------+------------------------------+
| | |
v v v
+------------------+ +------------------+ +------------------+
| Health Insurance | | Health Provision | | Aged Care |
| (73% of Revenue) | | (20% of Revenue) | | (7% of Revenue) |
+------------------+ +------------------+ +------------------+
Financial Analysis: What the Numbers Show
Financial data covering the five-year period from 2021 to 2025 demonstrates strong revenue expansion alongside a sharp recovery in statutory profitability following exceptional asset impairments recorded in 2022. Turnover expanded from £12.900 billion in 2021 to £18.154 billion in 2025, representing a cumulative increase of 40.7% at actual exchange rates.
Statutory results exhibit significant volatility in 2022, when the company reported a pre-tax loss of £306 million. This reduction was caused by approximately £1.0 billion in non-cash asset impairments across UK Dental (£646 million), Bupa Chile (£161 million), Australian Care Provision (£103 million), and UK Care Services (£90 million), triggered by rising discount rates and sector workforce challenges. Profitability recovered in subsequent periods, with profit before tax reaching £717 million in 2023, £1.156 billion in 2024, and £1.147 billion in 2025.
| Financial Metric | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Turnover / Revenue | £12,900m | £14,000m | £15,100m | £16,900m | £18,154m |
| Operating Profit | Not on record | Not on record | Not on record | Not on record | £1,180m |
| Profit Before Tax | £537m | (£306m) | £717m | £1,156m | £1,147m |
| Profit After Tax | £438m | (£421m) | £538m | £867m | Not on record |
| Fixed Assets | £2,248m | £2,210m | £3,605m | £3,711m | £2,207m |
| Cash & Cash Equivalents | Not on record | £1,479m | £2,278m | £1,992m | Not on record |
| Net Assets | Not on record | £6,576m | £6,998m | £7,713m | Not on record |
| Operating Cash Flow | £939m | £1,039m | £1,304m | £1,414m | £1,426m |
| Solvency II Coverage | 179% | 181% | 175% | 176% | 187% |
| Leverage (excl. IFRS 16) | 20.4% | 19.1% | 20.6% | 16.6% | 16.1% |
Operating cash generation has remained consistent, rising from £939 million in 2021 to £1.426 billion in 2025. Balance sheet leverage (excluding IFRS 16 lease liabilities) improved from 20.4% in 2021 to 16.1% in 2025. The Solvency II capital coverage ratio stood at 187% at year-end 2025, operating well above the target internal working range of 140% to 170%.
Segmental performance for 2025 reveals that Bupa Asia Pacific generated £6.316 billion in revenue (underlying profit of £459 million), Europe and Latin America produced £6.016 billion (underlying profit of £461 million), and Bupa Global, India and UK contributed £5.756 billion (underlying profit of £321 million).
Ownership, Governance, and Board Structure
Bupa Finance PLC is a public limited company incorporated in England and Wales on 13 January 1993. Its registered office is at 1 Angel Court, London, EC2R 7HJ.
The immediate and ultimate parent undertaking is The British United Provident Association Limited (Bupa). Bupa is a company limited by guarantee without share capital. Consequently, Bupa Finance PLC has no external equity shareholders; all issued share capital (£200 million) is held by the ultimate parent. Profit generated by the operating group is either retained for capital strength or paid out as interim dividends to fund parent obligations and customer health initiatives. Interim dividends paid were £52 million in 2021, £89 million in 2022, £134 million in 2023, £164 million in 2024, and £212 million in 2025. No final dividends were proposed in any of these years.
The board of directors recorded as of 31 December 2025 comprises four members:
- C Binmore (Director)
- G M Evans (Director)
- S M Fielding (Director)
- J A Lenton (Director)
Company secretarial duties are handled by C R Campbell. The board applies the corporate governance arrangements operated by Bupa, adopting relevant provisions of the UK Corporate Governance Code. Under s.172 Companies Act 2006, the directors explicitly record how stakeholder interests, including bondholders, regulators, and internal business units, are factored into treasury decisions, debt refinancing, and capital distribution.
Directors' remuneration across the group totaled £6.594 million in 2025 (2024: £6.165 million), which included £3.675 million in base emoluments and £2.879 million receivable under long-term incentive plans. The highest-paid director received total remuneration of £3.521 million in 2025 (2024: £3.362 million).
Recent Corporate Activity and Statutory Filings
PricewaterhouseCoopers LLP served as external auditor across the 2021 to 2025 reporting periods, issuing unqualified audit opinions on both group and standalone company financial statements. Group materiality for the 2025 audit was set at £57.3 million, based on 5% of profit before tax.
Treasury and capital market transactions remain the primary driver of corporate filings for this entity. Key debt capital transactions include:
- November 2025: Issuance of £400 million 6.625% Tier 2 subordinated notes due 2045. Concurrently, the company executed a £400 million debt buyback targeting its 2026 Tier 2 notes and 2027 senior notes, leaving £108 million of the 2026 Tier 2 notes and £192 million of the 2027 senior notes outstanding.
- October 2024: Fitch upgraded the Issuer Default Rating of Bupa Finance PLC to A (from A-).
- April 2024: Redemption of a £300 million senior bond upon maturity, funded via existing cash and drawings under bank facilities.
- October 2023: Issuance of €500 million senior notes.
- September 2021: Issuance of £300 million Restricted Tier 1 capital notes, combined with a £250 million partial buyback of Tier 2 debt maturing in 2023.
The group maintains a £900 million Revolving Credit Facility (RCF) maturing in December 2028, which was fully undrawn as of 31 December 2024 and 31 December 2025.
No statutory winding-up notices, petitions, or administration appointments appear in The Gazette records for Bupa Finance PLC.
Risk Indicators and Key Monitoring Points
Corporate intelligence surveillance on Bupa Finance PLC centres on regulatory liabilities, health claims inflation, and global debt market pricing. A professional reviewing the entity should monitor the following risk factors:
1. Chilean Regulatory Settlement (Isapre Cruz Blanca): Historical uncertainty surrounding a Chilean Supreme Court ruling on insurance premium risk factor tables resulted in a contingent liability disclosure in 2022 and 2023. Following local legislation in May 2024, a provision of £215 million was initially recognised. Upon formal regulator approval of a 13-year repayment plan in October 2024, this was reclassified to trade payables as a discounted financial liability of £181 million (£187 million expense impact in 2024).
2. Goodwill and Intangible Impairment Sensitivity: The group holds £193 million in goodwill (2025) and significant intangible assets. Key audit matters highlighted by PricewaterhouseCoopers LLP identify Bupa Dental Care UK as a cash-generating unit requiring ongoing impairment review due to clinician recruitment constraints and NHS contract pressures.
3. Insurance Claims Inflation & Underwriting Risk: Rising medical costs across international healthcare markets directly influence the Combined Operating Ratio (COR), which stood at 94% in 2025 (2024: 95%). Short-tail contract structures allow annual repricing, but regulatory caps in certain jurisdictions can create temporary margin compression.
4. Property Valuation Volatility: The group holds substantial freehold properties (£2.207 billion in 2025) across care homes, hospitals, and offices. Valuations are sensitive to occupancy rates, yield expansion, and care home operational costs.
+--------------------------------------------------------------------------------+
| DUE DILIGENCE REVIEW FRAMEWORK |
+--------------------------------------------------------------------------------+
|
+--------------------------------+--------------------------------+
| | |
v v v
+-------------------------------+ +------------------------------+ +------------------------------+
| 1. Regulatory Monitor | | 2. Treasury & Debt | | 3. Valuation & Impairment |
| Check Chilean Isapre payables | | Monitor Tier 2 notes (2045) | | Assess UK Dental CGU carrying|
| schedule and local health | | and undrawn £900m RCF for | | values against local NHS cost|
| policy changes in UK/Spain. | | refinancing pressure. | | inflation. |
+-------------------------------+ +------------------------------+ +------------------------------+
Advisers conducting counterparty credit risk reviews should utilize a decision framework focused on solvency metrics, debt maturities, and regulatory exposures:
- Step 1: Regulatory Solvency Assessment. Confirm the Solvency II coverage ratio remains comfortably above the target 140% threshold (187% in 2025).
- Step 2: Debt Profile & Refinancing Check. Examine upcoming bond maturities (£108 million remaining Tier 2 due 2026; £192 million senior notes due 2027) against available cash reserves and undrawn bank lines.
- Step 3: Impairment Monitoring. Track annual impairment reports for healthcare provision assets, particularly within the UK dental network.
- Step 4: Real-time Alerting. Establish automated monitoring for filing updates, charge registrations, and rating agency actions.
How a Professional Validates This Entity: Manual vs Corp Intel
To conduct due diligence on Bupa Finance PLC manually, a corporate intelligence analyst or credit analyst must complete several disaggregated steps:
1. Search the Companies House service to pull annual reports, form AA02/AA01 filings, and review debt instruments recorded on the charges register.
2. Query The Gazette for statutory notices, insolvency filings, or capital reduction notifications.
3. Search the FCA's portal and market news providers for debt listing prospectuses, bond pricing notices, and rating agency actions (Moody's and Fitch).
4. Manually extract segmental financial metrics from lengthy consolidated IFRS financial statements to isolate holding company debt obligations from operating subsidiary performance.
Using Corp Intel, this process is consolidated into a single automated intelligence workflow. Professionals enter the company profile via the company search portal or access Bupa Finance PLC directly.
Corp Intel extracts structured financial tables, parses key audit matters from auditor reports, monitors debt charges via the company charge check tool, and cross-references regulatory court petitions using the winding up petition search engine. Ongoing changes in board composition, credit ratings, or statutory filings can be tracked automatically by setting up free company monitoring.
Frequently Asked Questions
What is the primary function of Bupa Finance PLC within the group?
Bupa Finance PLC operates as the central treasury and financing entity for the Bupa Group. It issues public debt securities, manages bank facilities, and channels liquidity to operating subsidiaries across international healthcare markets.
Who owns Bupa Finance PLC?
Bupa Finance PLC is a wholly owned subsidiary of The British United Provident Association Limited (Bupa). The ultimate parent is a company limited by guarantee with no equity shareholders. All profits are reinvested into healthcare operations or retained to maintain capital strength.
What is Bupa Finance PLC's capital and solvency position?
As of 31 December 2025, the Bupa Group reported a Solvency II capital coverage ratio of 187%, which is above its target working range of 140% to 170%. Leverage excluding IFRS 16 lease liabilities stood at 16.1%.
Has Bupa Finance PLC experienced recent asset impairments?
In 2022, the group recorded approximately £1.0 billion in non-cash asset impairments across UK Dental (£646 million), Bupa Chile (£161 million), Australian Care Provision (£103 million), and UK Care Services (£90 million). Profitability has since recovered, reaching pre-tax profits of £1.147 billion in 2025.
What was the outcome of the Chilean Isapre litigation for Bupa?
Following a Chilean Supreme Court ruling regarding insurance pricing, Bupa Chile reached a regulatory resolution in October 2024. A formal 13-year repayment plan was approved, resulting in the reclassification of a £215 million provision into an £181 million discounted financial liability recorded within payables at year-end 2024.
How does Bupa Finance PLC manage its debt maturity structure?
In November 2025, the company issued £400 million of 2045 Tier 2 notes and completed a £400 million buyback of its 2026 Tier 2 and 2027 senior notes. It also maintains an undrawn £900 million Revolving Credit Facility maturing in December 2028.
---
To review complete financial histories, track debt charges, or set up automated alerts for Bupa Finance PLC, access the Corp Intel Company Record or activate free company monitoring.-----------